Skip to main content
Clinical Trials/NCT03899623
NCT03899623UnknownNot Applicable

Multi-modal Imaging and Artificial Intelligence Diagnostic System for Multi-level Clinical Application

Zhongshan Ophthalmic Center, Sun Yat-sen University1 site in 1 country3,000 target enrollmentStarted: April 23, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
3,000
Locations
1
Primary Endpoint
The diagnostic sensitivity, specificity and ROC curve of the artificial intelligence(AI) system compared with reference standard (ophthalmologist).

Study Overview

Brief Summary

This study is to build an multi-modal artificial intelligence ophthalmological imaging diagnostic system covering multi-level medical institutions. We are going to evaluate this system in an evidence-based medicine view, taking diabetic retinopathy as an example. And clinical diagnostic criteria will be made based on this multi-modal artificial intelligence imaging diagnostic system. The study is designed as a cross-sectional study involving 1,000 normal individuals, 1,000 diabetes patients without ocular complications, and 1,000 with diabetic ocular complications. Statistical analysis of the diagnostic sensitivity and specificity of the artificial intelligence system will be made, and ROC curve wil be draw.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Group A(normal individuals): Meet all the items 1 ~ 5 below
  • No familial or hereditary retinopathy;
  • No history of ocular trauma and / or history of ocular disease (except for mild to moderate refractive errors and / or age-related cataracts);
  • No drug use history that may cause side effects of retina (such as chloroquine, hydroxychloroquine, chlorpromazine, rifampin, etc.); 4 binocular diopter ≤ ± 6.00D; No systemic diseases that may affect the retina.
  • Group B(diabetes patients without ocular complications): meet any of 1 to 3, and both 4 to 5 items
  • Diagnosed with type 1 diabetes for more than 5 years;
  • Diagnosed with type 2 diabetes patients;
  • Diagnosis of gestational diabetes patients;
  • Without systemic disease that may affect the retina except for diabetes;
  • Meet the standards of 1 to 4 items.
  • Group C(patients with diabetic ocular complications): meet with any of 1 to 3, and all 4 to 6 items
  • Diagnosed with type 1 diabetes for more than 5 years;
  • Diagnosed with type 2 diabetes patients;
  • Diagnosis of gestational diabetes patients;
  • Meet the guidelines for diagnosis and treatment of diabetic retinopathy in any stage of diabetic retinopathy and / or diabetic macular edema.
  • Without systemic disease that may affect the retina except for diabetes;
  • A group to meet the criteria for 1 to 4 items.

Exclusion Criteria

  • Refractive pathway is turbid, so that fundus image can not be clearly photographed;
  • With other fundus diseases and / or other diseases that seriously affect the visual function;
  • Any eye infection, such as conjunctivitis, keratitis, scleritis, endophthalmitis, acute and chronic dacryocystitis, or eye injury;
  • Serious systemic diseases such as diabetes, hypertension, heart failur,renal failure;
  • Can not cooperate with the examiner due to mental or other reasons.

Outcomes

Primary Outcomes

The diagnostic sensitivity, specificity and ROC curve of the artificial intelligence(AI) system compared with reference standard (ophthalmologist).

Time Frame: It will take 15~20min for each subject to take the exams.

Sensitivity: the percentage of diabetic retinopathy(DR) patients who are correctly identified as having the condition by AI. Sensitivity=True positive/(True positive+False negative). Specificity: the percentage of healthy people who are correctly identified as not having the condition by AI. Specificity=True negative /(True negative +False positive). The ROC curve was plotted with true positive rate (sensitivity) as the ordinate and false positive rate (1-specificity) as the abscissa.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jin Yuan

Principal Investigator

Zhongshan Ophthalmic Center, Sun Yat-sen University

Study Sites (1)

Loading locations...

Similar Trials